Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giacomo Ruotolo

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Current Cardiology Reports|October 16, 2002
Dyslipidemia of the metabolic syndromeGiacomo Ruotolo, Barbara V Howard
Endocrinology and Metabolism Clinics of North America|January 9, 2004
Obesity and dyslipidemiaBarbara V Howard, Giacomo Ruotolo, David C Robbins
Acta Diabetologica|February 4, 2011
Lack of association of apoE ε4 allele with insulin resistanceFrancesca Ragogna, Guido Lattuada, Giacomo Ruotolo, et al.
The American Journal of Cardiology|May 3, 2014
Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemiaTamio Teramoto, Masakazu Takeuchi, Yoji Morisaki, et al.
Haematologica|December 6, 2006
Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian populationArmando D'Angelo, Giacomo Ruotolo, Paola Garancini, et al.
European Heart Journal|June 27, 2015
Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndromeAmit V Khera, John S Millar, Giacomo Ruotolo, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 23, 2021
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart DiseaseJeremy D Furtado, Giacomo Ruotolo, Stephen J Nicholls, et al.
Diabetes Care|March 1, 2003
Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart StudyHelaine E Resnick, Kristina Jones, Giacomo Ruotolo, et al.
Diabetes Care|July 31, 2009
Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individualsLorenzo Piemonti, Giliola Calori, Guido Lattuada, et al.
The Journal of Pharmacy and Pharmacology|June 26, 2014
Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adultsJeffrey G Suico, Ming-Dauh Wang, Stuart Friedrich, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Current Cardiology Reports|October 16, 2002
Dyslipidemia of the metabolic syndromeGiacomo Ruotolo, Barbara V Howard
Endocrinology and Metabolism Clinics of North America|January 9, 2004
Obesity and dyslipidemiaBarbara V Howard, Giacomo Ruotolo, David C Robbins
Acta Diabetologica|February 4, 2011
Lack of association of apoE ε4 allele with insulin resistanceFrancesca Ragogna, Guido Lattuada, Giacomo Ruotolo, et al.
The American Journal of Cardiology|May 3, 2014
Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemiaTamio Teramoto, Masakazu Takeuchi, Yoji Morisaki, et al.
Haematologica|December 6, 2006
Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian populationArmando D'Angelo, Giacomo Ruotolo, Paola Garancini, et al.
European Heart Journal|June 27, 2015
Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndromeAmit V Khera, John S Millar, Giacomo Ruotolo, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 23, 2021
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart DiseaseJeremy D Furtado, Giacomo Ruotolo, Stephen J Nicholls, et al.
Diabetes Care|March 1, 2003
Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart StudyHelaine E Resnick, Kristina Jones, Giacomo Ruotolo, et al.
Diabetes Care|July 31, 2009
Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individualsLorenzo Piemonti, Giliola Calori, Guido Lattuada, et al.
The Journal of Pharmacy and Pharmacology|June 26, 2014
Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adultsJeffrey G Suico, Ming-Dauh Wang, Stuart Friedrich, et al.
Pageof 6